References
- Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult t-cell leukemia–lymphoma. A report from the Lymphoma Study Group (1984–1987). Br J Haematol. 1991;79:428–437.
- Utsunomiya A, Nakano N, Takatsuka Y. Recent advances in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia–lymphoma. J Hematopoeitic Cell Transpl. 2015;4:39–46.
- Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O. Clinical trials of adult T-cell leukemia/lymphoma treatment. Leuk Res Treatment. 2012;2012:932175. doi:10.1155/2012/932175.
- Tokunaga M, Uto H, Takeuchi S, Nakano N, Kubota A, Tokunaga M, etet al. Newly identified poor prognostic factors for adult T-cell leukemia–lymphoma treated with allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2017;58:37–44.
- Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2013. The Japanese Data Center for Hematopoietic Cell Transplantation. The Japan Society for Hematopoietic Cell Transplantation 2014 March 15, 2014.
- Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia–lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–1741.
- Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2011;116:1369–1376.
- Bazarbachi A, Cwynarski K, Boumedil A, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant. 2014;49:1266–1268.
- Phillips A, Shapira I, Willim RD, et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010;116:3438–3446.
- Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016;51:205–211.
- Shiratori S, Kosugi-Kanaya M, Shigematsu A, et al. Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2015;56:2592–2597.
- Shigematsu A, Kobayashi N, Yasui H, et al. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant. 2014;20:801–805.
- Nakamura Y, Tanaka Y, Tanaka M, et al. Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Int J Hematol. 2016;103:436–443.
- Choi I, Eto T, Tanosaki R, et al. Unrelated bone marrow transplantation with reduced intensity conditioning regimen for elderly patients with adult T-cell leukemia/lymphoma, feasibility study with two-year follow up data. 19th Congress of EHA, Milan, Italy; 2014, Abstract 1113.
- Fukushima T, Itonaga H, Moriuchi Y, et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol. 2013;97:485–490.
- Fujiwara H, Kawada H, Matsushita K, et al. Case of a patient with progressive adult T-cell Leukemia/Lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor. Int J Hematol. 2005;82:357.
- Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia–lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–842.
- Sugio T, Kato K, Aoki T, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:1608–1614.